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Abstract
Background: Lung cancer is a leading cause of cancer morbidity and mortality worldwide. Several studies have
suggested that Human papillomavirus (HPV) infection is an important risk factor in the development of lung cancer.
In this study, we aim to address the role of HPV in the development of lung cancer mechanistically by examining
the induction of inflammation and epithelial-mesenchymal transition (EMT) by this virus.
Methods: In this case-control study, tissue samples were collected from 102 cases with lung cancer and 48
controls. We examined the presence of HPV DNA and also the viral genotype in positive samples. We also
examined the expression of viral genes (E2, E6 and E7), anti-carcinogenic genes (p53, retinoblastoma (RB)), and
inflammatory cytokines in HPV positive cases.
Results: HPV DNA was detected in 52.9% (54/102) of the case samples and in 25% (12/48) of controls. A significant
association was observed between a HPV positive status and lung cancer (OR = 3.37, 95% C.I = 1.58–7.22, P = 0.001).
The most prevalent virus genotype in the patients was type 16 (38.8%). The expression of p53 and RB were
decreased while and inflammatory cytokines were increased in HPV-positive lung cancer and HPV-positive control
tissues compared to HPV-negative lung cancer and HPV-negative control tissues. Also, the expression level of E-cad
and PTPN-13 genes were decreased in HPV- positive samples while the expression level of SLUG, TWIST and N-cad
was increased in HPV-positive samples compared to negative samples.
Conclusion: Our study suggests that HPV infection drives the induction of inflammation and EMT which may
promote in the development of lung cancer.
Keywords: Human papilloma virus, Lung Cancer, Tumour development, Inflammatory cytokines, Epithelial-
mesenchymal transition (EMT)
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Background
Lung cancer is one of the leading causes of cancer mor-
bidity and mortality worldwide [1]. There are several
types of primary lung cancer which, are divided into two
main groups; small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). NSCLC are divided into
three common types; squamous cell carcinoma, large cell
carcinoma and adenocarcinoma [2]. The pathogenesis of
lung cancer is a complex multifactor process with both
genetic and environmental factors playing a major role
[3]. Infectious agents are emerging as key drivers in the
development of cancer [4–7]. Previously, numerous in-
fectious agents have been shown to be involved in a
myriad of lung diseases including cancer, Idiopathic Pul-
monary Fibrosis (IPF) and Chronic Obstructive Pulmon-
ary Disease (COPD) [8–10].
Human papilloma virus (HPV) is one of the most im-
portant human oncogenic viruses [11], which has previ-
ously been shown to be associated with numerous
cancers including lung, breast and prostate [1, 6, 11–13].
The HPV genome is divided into three main sections;
long control region (LCR), early region (E) encoding E1,
E2, E4–E7, and late region (L) consisting of L1 and L2
[14]. E6 and E7 are the oncoproteins that act as stimu-
lating factors for host cell proliferation [15]. E6 interacts
with p53 and BCL2, while E7 interacts with retinoblast-
oma (RB); both of which lead to enhanced cell prolifera-
tion, resistance to apoptosis and chromosomal instability
[16, 17]. These viral proteins enhance tumour develop-
ment by promoting inflammation and epithelial-
mesenchymal transition (EMT) [18, 19].
In response to harmful stimuli and invading patho-
gens, the innate immune system becomes activated
through a variety of receptors, leading to the generation
of an acute inflammatory response. This inflammation
aids in the removal and clearance of the stimulus. How-
ever, should the stimulus fail to be removed the develop-
ment of chronic inflammation occurs which is strongly
associated with cancer [20].
Chronic inflammation as a result of viral infection is
responsible for an estimated 25% of all human cancers
[21, 22]. In response to viral infection the generation of
a pro-inflammatory response involves activation of nu-
merous transcription factors including NF-κB and the
secretion of numerous pro-inflammatory cytokines and
metabolites including transforming growth factors like
beta (TGF-β), interleukin 1 (IL-1), IL-6, IL-11,
Tumour necrosis factor α (TNF-α) and reactive
oxygen-nitrogen species (RONS) - all of which play a
pro-tumorigenic role in the context of chronic inflam-
mation. This pro-inflammatory tissue microenviron-
ment results in the suppression of anti-humoral
immunity and also the promotion of tumour develop-
ment and metastasis [7, 23, 24].
The second facet of high-risk HPV (hr-HPV) related
tumour development is EMT, which plays an important
role in solid cancer progression through multiple bio-
chemical changes. EMT is well known to enhance cell
migration, invasion and cancer development [25].
There are several genes involved in EMT, including
SLUG, PTPN13, E-cad, N-cad and TWIST. SLUG protein
is involved in important cellular events including EMT
and also has anti-apoptotic activity [26]. PTPN13 interacts
with Fas receptor which is indirectly involved in inhibition
of programmed cell death [27]. E-cad and N-cad expres-
sion levels have also been connected with survival mecha-
nisms and metastasis of lung cancer cells [28, 29].
In this study we investigated, for the first time, the role
of hr-HPV in EMT and lung tumour development. We
also assessed the prevalence of HPV in lung tumour
samples; examining the expression level of viral and cel-
lular genes and the associations between these expressed
genes in EMT and lung tumour development.
Methods
Study design and samples
This case-control study was conducted between Novem-
ber 2017 and September 2018. One hundred and two lung
cancer samples and forty-eight normal lung tissue sam-
ples. Control samples were age and sex matched, with the
tissue samples collected from a peripheral region of the
surgically removed lung cancers and non-cancer patients
with fibrosis. All samples, cases and controls, were fresh
tissue with a Tumor Proportion Score (TPS) > 50%. Con-
trol samples were age and sex matched. The TNM system
was used to denote the stage of cancer as decided by a
consultant oncologist and oncological surgeon. Gender,
age, smoking status, tumour type and tumour stage were
clinical parameters of patients that are shown in (supple-
mentary materials). We had no medical records of HPV
infection before cancer diagnosis.
Extraction of nucleic acids
Total DNA extraction from tissue samples was per-
formed by QIAamp® DNA Mini Kit (Qiagen, Hilden,
Germany). Quality of extracted DNA was assessed by
conducting PCR for β-globin as described before [30].
All samples were deemed suitable for molecular analysis
due to β-globin gene amplification.
Total RNA extraction was conducted by RNeasy Mini
Kit (Qiagen, Hilden, Germany).
HPV detection and genotyping
HPV genome detection was conducted using PCR for L1
and E7 genes [31]. HPV genotyping was performed by
INNO-LiPA HPV Genotyping v2 test (Innogenetics,
Ghent, Belgium).
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Determination of HPV genome physical status
To determine the physical status of the HPV genome,
the E2/E6 ratio was used. An E2/E6 ratio > 0 and < 1 in-
dicates that the virus is in a mixed physical state, with
both episomal and integrated forms of the virus [32].
Quantitative real-time PCR
mRNA level detection of viral genes
Total RNA was extracted and purified from the tissue by
using RNEasy Mini kit (QIAGEN, Hilden, Germany).
For cDNA synthesis, 1 μg of total RNA was reverse tran-
scribed using the QuantiNova Reverse Transcription Kit
(QIAGEN, Germany). CDNA synthesis was performed
in a thermal cycler in the following order: 27 °C for 10
min, 38 °C for 15 min, 44 °C for 40 min, 72 °C for 15 min.
All the primers which were used to detect viral genes
(E2, E6 and E7) are listed in a table in the (supplemen-
tary materials). To detect viral genes E2, E6 and E7,
Quantitative SYBR green TaqMan Universal PCR Master
Mix® (QIAGEN, Germany), one step RT-PCR® kits
(QIAGEN, Hilden, Germany) and QuantiNova Reverse
Transcription® Kit were used, respectively.
For viral genes we used serial dilutions of E2, E6 and
E7 genes cloned in PUC57 vector (GenScript, Jiangsu,
China). Serial dilution was containing equivalent
amounts of these genes from 72 to 865 million copies
per reaction, served as a standard control.
mRNA level detection of cellular genes
cDNA was synthesized using the PrimeScript First
Strand cDNA synthesis kit (TaKaRa Bio, Kusatsu, Japan).
Quantitative RT-PCR analyses were performed using the
Power SYBR Green PCR Master Mix (TaKaRa Bio,
Kusatsu, Japan). The relative expression level of each
mRNA was normalized using GAPDH. The primers are
listed in supplementary materials.
Enzyme linked immunosorbent assay (ELISA)
For tissue homogenization, all fresh tissue samples were
weighed and the tissue lysate was prepared according to
the manufactures protocol (Invitrogen, CA, USA). Ap-
proximately 50 μg of each tissue was excised and washed
with ice-cold PBS.
The level of p53, RB, IL-1, IL-6, IL-11, NF-kB, NF-κ
PTPN13, E-cadherin, N-cadherin and TWIST was
assessed using Abcam’s p53 Simple Step ELISA® Kit
(Abcam, Cambridge, MA, USA), Human Retinoblastoma
ELISA® kit (Sigma-Aldrich, Saint Louis, USA), Human
Retinoblastoma ELISA® kit (Sigma-Aldrich, Saint Louis,
USA), Human IL-6 ELISA® Kit, Human IL-1 beta ELIS
A® Kit, Human IL-11 ELISA® Kit, NF-kB p65 Transcrip-
tion Factor Assay® Kit (Abcam, Cambridge, MA, USA),
Human Tyrosine-Protein Phosphatase Non-Receptor
Type 13 (PTPN13) ELISA Kit (MyBiosource, USA),
Human E-Cadherin, N-Cadherin ELISA Kit (Abcam,
Cambridge, MA, USA).and TWIST ELISA Kit (Aviva
Systems Biology, CA, USA).
Quantification of RONS
The RONS level was assessed by OxiSelect™ Intracellular
ROS/RNS Assay kit (Cell Biolabs, Inc., San Diego, CA).
For this purpose, cell lysate was used and preparation of
this based on Kit instructions.
Statistical methods
Continuous variables are presented as mean ± standard
deviation and categorical variables are presented as N
(%). Normality test was checked using Kolmogorov–
Smirnov test for the continuous variables. For compar-
ing the central tendency (e.g. mean for normal and me-
dian for non-normal variables) between two groups,
two-independent samples t-test or Mann-Whitney non-
parametric test and between more than two groups,
one-way ANOVA or kruskal-wallis test were used. Chi-
square/ or Fisher exact test was performed for assessing
the associations of the categorical variables. The unit of
all expression RT-PCR is (2^-DCt)*1000. Internal
normalization was performed using an internal house-
keeping or reference gene (GAPDH) and external
normalization was applied by standardized approach. In
addition, correlation analysis was done by Spearman’s
correlation coefficient between viral and cellular factors.
All of statistical analyses were analysed using GraphPad
Prism 6 and STATA software versions 11.2. False dis-
covery rate was corrected by Benjamini-Hochberg ap-
proach for multiple comparisons. A two-sided P-value of
less than 0.05 was considered as statistical significance.
Results
In this case-control study, we examined 102 lung cancer
cases and 48 controls, with the mean ± SD age; 56.36 ±
12.49 and 57.0 ± 12.24, respectively. Seventy-four (72.5%)
of the cases and 31 (64.5%) of the controls were male,
respectively. The cases and control groups were matched
based on age (p = 0.77). There were three types of lung
tumour tissues; squamous-cell carcinoma (51.9%),
adenocarcinoma (32.3%) and SCLC (15.7%). The highest
and lowest stages of cancer in this study were IIIB
(30.4%) and IA and IIB (1.9%) respectively. HPV DNA
was detected in 52.9% of the lung cancer specimens and
in 25% of control samples. There was a significant asso-
ciation between the presence of HPV and lung tumour
(OR = 3.37, 95% C.I = 1.58–7.22, P = 0.001). Genotype 16
was the most frequently isolated genotype in both cases
(38.8%) and controls (50%). No significant association
was observed between all genotypes and the occurrence
of lung tumour (p = 0.651) (supplementary materials).
HPV DNA was detected in 55.6% (30 of 53) of
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squamous-cell carcinoma samples, 54.5% (18 of 33) of
adenocarcinoma samples and 37.5% (6 of 16) of SCLC
samples. The association between HPV infection and
histopathological types of tumour was not statistically
significant (p = 0.434). There were no significant differ-
ences in the frequency distributions of lung tumour
stages between HPV+ and HPV- groups (p = 0.163).
More information is presented in supplementary
materials.
In the HPV+ lung carcinoma patients, the virus was
present in its integrated form in 27.8% of cases. The in-
cidences of episomal and mixed forms of HPV genome
were 5.5 and 66.7% respectively. In the control HPV+
group, the incidence of HPV genome status was 25, 0
and 75% integrated, episomal and mixed forms of HPV
respectively (Table 1). The gene expression level of viral
genes in both types and stages of lung tumour are shown
in Table 2. The highest level of viral gene expression
was that of E7 which was most highly observed in stage
IV samples (mean ± SD:13.56 ± 5.13). The lowest level of
viral gene expression examined was E6 in stage IB sam-
ples (mean ± SD: 3.0 ± 1.75). The gene expression level
of viral factors E2 and E6 were highest in stage IIB and
stage IV respectively. Stratification of the samples based
on the tumour type reveals the expression level of E7 in
adenocarcinoma samples (mean ± SD: 11.94 ± 4.93) and
E2 in SCLC (mean ± SD: 3.67 ± 1.15) were the highest
and lowest respectively (Table 2). The expression level
of viral genes in control samples and tumour samples
are illustrated in Fig. 1.
In Table 3, the level of cellular factors such as
tumour-suppressors (Rb and p53), inflammatory factors
(ILs, IFNs, TGF-β, TNF-α, and NF-κB), EMT factors
(PTPN13, SLUG, E-cad, N-cad and TWIST) and RONS
are presented. The protein levels of Rb and p53 were
significantly downregulated in HPV+ cases and HPV+
controls compared with HPV- cases and controls (p <
0.001). The level of inflammatory factors, were consider-
ably higher in HPV+ cases and controls compared to the
HPV- cases and controls groups. The levels of EMT in-
volved factors found to be significantly higher in HPV
infected group compare to HPV non-infected group
(p < 0.001 for all). Among the EMT involved genes,
PTPN13 and E-cad were significantly downregulated in
HPV+ cases and controls compared with HPV- cases
and controls (p < 0.001). SLUG, N-cad and TWIST were
significantly upregulated in HPV+ cases and controls
compared with HPV- cases and controls (p < 0.05). The
highest expression levels were related with SLUG, N-cad
and TWIST in HPV+ compared with HPV- groups (fold
change > 15; p < 0.001 for all). More details are pre-
sented in Fig. 2. Significant negative correlations were
observed between the expression level of viral genes and
the protein expression levels of regulatory host proteins,
Rb and p53. Among the inflammatory factors examined,
the correlations between E2 expression level with IL-1
Table 1 Physical status of HPV genome in cases and controls
Cases (%) Controls (%) Total number (%) P-value
Integrated 15/54 (27.8)
Tumour Stages:
IA (N = 0)
IB (N = 2)
IIA (N = 0)
IIB (N = 3)
IIIA (N = 1)
IIIB (N = 3)
IV (N = 6)
Tumour Types:
Adenocarcinoma (N = 4)
Squamous-cell carcinoma (N = 6)
Small-cell lung carcinoma (N = 5)
3/12 (25) 18/66 (27.3) 0.845
Episomal 3/54 (5.5)
Tumour Stages:
IA (N = 0)
IB (N = 1)
IIA (N = 0)
IIB (N = 2)
IIIA (N = 0)
IIIB (N = 0)
IV (N = 0)
Tumour Types:
Adenocarcinoma (N = 0)
Squamous-cell carcinoma (N = 2)
Small-cell lung carcinoma (N = 1)
0 3/66 (4.5) NA
Mixed 36/54 (66.7)
Tumour Stages:
IA (N = 1)
IB (N = 0)
IIA (N = 4)
IIB (N = 3)
IIIA (N = 7)
IIIB (N = 6)
IV (N = 15)
Tumour Types:
Adenocarcinoma (N = 5)
Squamous-cell carcinoma (N = 22)
Small-cell lung carcinoma (N = 9)
9/12 (75) 45/66 (68.2) 0.827
NA Not available
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and TNF-α were statistically significant, and the correla-
tions between IL-6 with E6 and E7 were statistically sig-
nificant (p < 0.01). The correlation between E2
expression level and PTPN13 was positive but with
SLUG, E-cad, N-cad and TWIST was negative. The ex-
pression level of E6 significantly correlated with the pro-
tein level of PTPN13. The expression level of E7 has the
negative correlation with E-cad and N-cad (p < 0.05).
Conversely, there were positive correlations between E6
gene expression and IL-1, IL-6, IFN-α and IFN-β protein
levels and RONS production (p < 0.05) (Table 3).
Discussion
Lung cancer is the primary cause of cancer death glo-
bally [33]. As such, there is a major unmet clinical need
for the development and discovery of prognostic bio-
markers for the diagnosis of lung cancer. This need is
underlined by the increased mortality rates which are
currently being observed in lung cancer worldwide [1,
15]. A plethora of carcinogens are responsible for the
initiation and development of various cancers. Of these,
viral infections are implicated in approximately 18–20%
of cancers [6, 11, 34]. While the prevalence of HPV in
lung carcinoma has shown in numerous studies, to date,
the role of hr-HPV in the promotion of EMT has not
yet been clearly identified. Here, we report for the first
time the association between HPV gene expression, in-
flammatory agents and cellular genes involved in EMT
in lung cancer tissue.
In the current study, 52.9% of lung tumour samples
were positive for HPV. Moreover, we demonstrate that
increased expression of HPV genes is associated with de-
creased expression of regulatory cellular genes, RB and
p53, and as a result increased risk of lung cancer. In an
investigation Nadji et al. (2007, Iran) studied 141 lung
carcinoma samples and 92 non-cancersamples as
Table 2 Comparison of HPV gene expression between stages, types of lung cancer, and controls
Cancer characteristic E2 E6 E7
Controls (n = 48) – 5.82 ± 2.48 (1) 8.36 ± 3.14 (1) 8.64 ± 4.30 (1)
Stages of Cancer (n = 102) IA 4.0 ± 1.27 (0.68) 9.0 ± 1.2 (1.07) 8.0 ± 1.89 (0.92)
IB 5 ± 1.0 (0.86) 3.0 ± 1.75 (0.36) 5.0 ± 0.57 (0.58)
IIA 8 ± 5.29 (1.37) 8 ± 2.45 (0.95) 9.75 ± 4.50 (1.13)
IIB 6.83 ± 2.32 (1.17) 9.1 ± 4.77 (1.09) 10.8 ± 6.59 (1.25)
IIIA 4.3 ± 3.02 (0.74) 8.54 ± 3.75 (1.02) 11.23 ± 4.95 (1.30)
IIIB 6.58 ± 4.08 (1.13) 8.13 ± 5.23 (0.97) 10.13 ± 5.17 (1.17)
IV 6.0 ± 3.83 (1.03) 12.33 ± 4.66 (1.47) 13.56 ± 5.13 (1.57)
P-value 0.585 0.301 0.643
Types of Cancer (n = 102) Adenocarcinoma 5.83 ± 3.69 (1) 9.67 ± 4.99 (1.17) 11.94 ± 4.93 (1.38)
Squamous-cell carcinoma 6.39 ± 3.69 (1.1) 8.63 ± 4.70 (1.03) 10.17 ± 5.57 (1.18)
Small-cell lung carcinoma 3.67 ± 1.15 (0.63) 9.0 ± 3.28 (1.07) 11.67 ± 5.09 (1.35)
P-value 0.466 0.762 0.504
Geometric Mean ± Standard Deviation (fold change), control group was as a reference group
Fig. 1 Comparison of E2, E6, and E7 gene expression in lung cancer versus control. NS: not significant at level of 0.05. (** P<0.01)
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controls. Results demonstrated that 25.6% of cases and
9.0% of controls were positive for HPV infection respect-
ively. The reported odds ratio for HPV infection was
3.48 (95% CI 1.522–7.958; P = 0.002) [3]. A similar study
by Argyria et al. (2017, Greece) investigated 67 lung tis-
sue samples from a Greek cohort, 12 SCLC and 55
NSCLC, and detected HPV in 3.0% of the samples; with
no association between HPV infection and lung cancer.
Other studies conducted in this region showed the
prevalence of HPV DNA rate was 0–61% [10]. Robinson
et al. (2016, USA) examined 70 NSCLC samples for de-
tection of viral DNA. They detected 69% of HPV DNA
in their samples [35]. A meta-analysis study which per-
formed by Syrjanen and his research team (2012)
showed the prevalence of HPV in Europe (16.9%) in
Australia (18.5%), in North America (12.5%) and in
China and Taiwan (37.7%). This study shows the role of
geographical distribution in HPV prevalence [36]. An-
other point in the current study, was the highest SCC
tumour type (51.9%) that is confirmed by a meta-
analysis study (Almasi et al. 2016, Iran) [37]. The most
common HPV genotypes detected in cancer patients are
HPV 16 and 18 [6, 38–40]. Previous investigations have
been confirmed this issue and also, a higher prevalence
of HPV-16 and 18 in Asian populations compared with
European populations (lung samples). It should be noted
that HPV-16 is the most prevalent genotype across all
geographical areas [38]. In another interesting study, the
presence of HPV DNA was examined in the exhaled
breath condensate (EBC) of lung cancer patients by
Table 3 Comparison of cellular factors levels between the studied groups
Cellular
factors
Patient with HPV +
(N = 54), Group 1
Patient with HPV -
(N = 48), Group 2
Control with HPV +
(N = 12), Group 3
Control with HPV -







P53 3.7 ± 2.01 16.02 ± 6.34 2.75 ± 1.54 15.11 ± 4.48 0.24, <
0.001
1.06, 0.677 0.18, <
0.001






TGF_β 18.57 ± 6.76 5.81 ± 3.27 9.33 ± 3.60 7.72 ± 3.29 2.4, 0.637 0.75, 0.189 1.2, <
0.001
IL-11 19.09 ± 6.08 5.25 ± 3.85 20.75 ± 7.34 3.78 ± 2.19 5.05, <
0.001
1.38, 0.382 5.49, <
0.001
IL-6 15.19 ± 5.30 3.88 ± 3.56 16.0 ± 6.03 4.33 ± 1.93 3.51, <
0.001
0.89, 0.931 3.69, <
0.001
IL-1 16.19 ± 5.88 4.04 ± 2.54 17.42 ± 7.26 4.44 ± 2.13 3.64, <
0.001
0.9, 0.957 3.92, <
0.001
TNF_α 12.83 ± 5.97 3.54 ± 3.33 21.5 ± 6.97 3.81 ± 1.43 3.36, <
0.001
0.93, 0.988 5.64, <
0.001
NFK_B 13.02 ± 5.89 4.15 ± 4.42 20.58 ± 6.54 4.17 ± 2.07 3.12, <
0.001




16.94 ± 7.37 2.92 ± 3.58 17.75 ± 5.31 2.67 ± 1.19 6.34, <
0.001
1.09, 0.993 6.64, <
0.001
IFN-Beta 16.09 ± 6.53 2.73 ± 2.37 16.83 ± 6.01 2.86 ± 1.39 5.62, <
0.001
0.95, 0.998 5.88, <
0.001






















ROS 17.37 ± 7.57 3.65 ± 2.93 19.25 ± 6.81 3.58 ± 1.93 4.85, <
0.001
1.02, 0.99 5.38, <
0.001
RNS 19.19 ± 8.43 4.48 ± 3.07 20.58 ± 6.06 4.14 ± 1.98 4.63, <
0.001
1.08, 0.987 4.97, <
0.001






F. change: Fold Change, Geometric Mean ± Standard Deviation, * comparison between group 1 versus group 4, + comparison between group 2 versus group 4, $
comparison between group 3 versus group 4. Control with HPV negative considered as the reference group. P is adjusted P-value based on the marginally
adjusted values by the Benjamini-Hochberg-FDR correction at α = 0.05, Bold P-values indicated as statistically significant at 0.05 level
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Carpagnano et al. (2011, Italy). Their results showed the
presence of HPV infection in 16.4% of samples. The au-
thors state that analysis of EBC for HPV infection repre-
sents a valid tool for the diagnosis of airway colonisation
[41].
Previous investigations have noted the physical status
of HPV DNA as an important marker for tumour pro-
gression in other cancers, such as breast cancer [32]. In
this study, the highest integrated form was seen in stages
III and IV in SCC samples (Table 1). Khodabandehlou
et al. previously reported on the physical status of HPV
genome in breast cancer samples, with 86% integrated
and 14% mixed forms respectively. The largest number
of integrated forms was in stage III and IV [6]. Detection
of HPV in its integrated form has also been reported in
several other cancers [30, 42, 43]. The integration of
HPV genome leads to changes in the expression of viral
oncogenes (E6 and E7), dysregulating of critical cell
cycle checkpoints, increased genetic instability in the
host and finally tumour development [44].
We examined the potential role of HPV in lung cancer
pathogenesis in two ways: i) the impact of HPV on the
expression of genes involved in EMT, ii) the impact of
HPV in the development of chronic inflammation and
microenvironment alteration. EMT promotes cancer de-
velopment through enhancing cellular migration and
Fig. 2 Comparison of the (a) cell factors expression, (b) ROS and RNS agents and (c) SLUG factors in HPV positive versus HPV negative subjects.
All the statistical comparisons were significant at level of 0.001 by independent T-test
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invasion [25, 45]. Oncoviruses are said to promote EMT
in particular cancer cells, enabling the spread of meta-
static cells from one location to another [21]. Hr-HPV
interacts with EMT factors to promote tumour develop-
ment. Our results demonstrate that the levels of genes
which promote EMT were substantially higher in HPV
positive groups compare to HPV negative groups (p <
0.001 for all) (Table 2). This situation could indicate that
the viral genes products/proteins may be involved in
stimulating of transcription of these genes. We have hy-
pothesized that hr-HPV promotes lung cancer develop-
ment indirectly through a variety of different
mechanisms. For example, HPV induce the production
of ROS that leads to cell survival and resistance to pro-
grammed cell death [46]. Previous studies have shown
that in lung cancers with impaired E-cadherin expres-
sion, the frequency of lymph node metastases was sig-
nificantly higher than tumours with high expression of
the E-cadherin [28, 47, 48]. In our study, expression of
E-cadherin in HPV+ samples were lower than HPV-
negative samples (Fig. 2), with viral E7 detection having
a negative correlation with E-cadherin levels (Table 2).
Unlike E-cadherin, protein levels of N-cadherin in
HPV+ samples were higher than HPV-negative samples;
which has previously been shown to be associated with
tumour development [49, 50]. On the other hand, TGF-
β lead to an increase of N-cadherin and the expression
of TGF-β in HPV+ samples was higher than HPV-
negative samples (Fig. 2, Table 3) [50]. Another import-
ant cellular factor is SLUG. This protein is overex-
pressed in numerous cancers [51]. High expression
levels of SLUG has also been shown to be associated
with reduced E-cadherin expression, high histologic
grade, lymph node metastasis, postoperative relapse and
shorter survival in patients with cancer [51–53]. SLUG
also has a role in inflammation-dependent tumour de-
velopment [54]. Our results demonstrate that the gene
expression level of this factor was higher in HPV+ sam-
ples than HPV-negative samples (Fig. 2, Table 3). Fur-
thermore, expression levels of SLUG have been shown
to correlate with lung tumour development and drug re-
sistance [55]. Our results show the over expression of
SLUG in HPV+ samples and direct correlation with E6
and E7 (Tables 2 and 4).
The tumour microenvironment is a key factor in
tumour development and several epidemiologic and clin-
ical researches have proposed a strong association be-
tween inflammation related to chronic infection and
lung cancer [20, 56–58]. This inflammation affects dif-
ferent aspects of tumor development such as angiogen-
esis, survival of malignant cells and even tumor response
to therapy [59, 60].
Our results demonstrate that the expression of numer-
ous inflammatory factors was higher in HPV+ samples
than HPV-negative samples (Table 3). Previously, Stone
et al. (2014, Brazil) have shown HPV dependant changes
in the tumour microenvironment. Their results showed
differences in local inflammation between HPV+ and
HPV-negative tumour tissues [56]. Liu et al. (2015,
China) have also studied the association between HPV
and chronic inflammation, demonstrating that chronic
inflammation was higher in oropharyngeal tumour tissue
compared to normal tissues (P < 0.001). They propose
that HPV infection could be considered as a biomarker/
risk in some cancers in individuals with chronic inflam-
mation [61]. Previous investigations have shown micro-
environmental alterations, caused by microorganisms,
such as cytokine secretion promote epithelial prolifera-
tion. This issue was demonstrated in HPV infection and
its persistence, which increases the risk of HPV trans-
mission and oropharyngeal carcinogenesis [62–64].
In the current study the highest expression level of
viral genes was in stage IV and the lowest level was in
Stage IA and IB. In the other words, viral genes can be
related to chronic inflammation and EMT (Table 2).
This issue indicates the important role of these gene
products in tumour development and metastasis. Al-
though HPV is an oncovirus, the presence of the virus
alone is insufficient for tumorigenesis. In order to pro-
mote cancer development, it is necessary to have a pro-
inflammatory tumour microenvironment which occurs
due to exposure to environmental factors or altered im-
munological mechanisms [20]. Also, should be noted
Table 4 Spearman’s correlation coefficient between viral factors
and cell factors
E2 E6 E7
P53 −0.19 −0.44** −0.34**
Rb −0.01 −0.36** −0.46**
TGF-β −0.14 −0.11 −0.04
IL-11 −0.27 0.22 0.19
IL-6 0.25 0.40** 0.35**
IL-1 0.47** 0.31* 0.30*
TNF_α −0.36* 0.03 0.05
NFκB −0.27 0.09 0.11
ROS 0.09 0.36** 0.39**
RNS 0.18 0.33** 0.34**
IFN-Alpha 0.02 0.27* 0.35**
IFN-Beta 0.14 0.35** 0.27*
PTPN13 0.09 −0.10* −0.21
SLUG −0.02 0.08 0.18
E-cad −0.13 −0.24 − 0.21*
N-cad −0.19 − 0.12 −0.08*
TWIST −0.13 −0.02 0.05
* p < 0.05; ** p < 0.01; *** p < 0.001
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that the possibility to get HPV after premalignant lesions
appear and how this concomitant infection may promote
cancer progression but not lung cancer origin.
A key risk factor associated with HPV infection is
smoking status. Previous studies have demonstrated the
relationship between smoking and HPV infection in
some cancers such as lung and cervical [1, 65]. In an in-
vestigation, relationship between HPV infection and
cigarette smoking was studied (by Xi et al.). They dem-
onstrated that HPV DNA load (type 16, 18) was associ-
ated with status of smoking, and current smokers had a
higher HPV DNA load compared to former smokers
[65].
Limitation of the current study were including:
i) Limitations on the number of cases considered for
the study and the lack of statistical representation for
some tumor stages; ii) protein and RNA samples are
pooled representation of the different cell types from the
original tumor/control tissue; iii) the absence of medical
information regarding a HPV infection before cancer
diagnosis for the patients analyzed in this research.
Conclusion
In summary, the presence of HPV was detected in 52.9%
of lung cancer samples among which most were at stage
III and IV (73.5%). Infection of HPV directly promotes
local inflammation which in turn promotes tumorigen-
esis and cancer development. We demonstrate that HPV
is associated with lung cancer development, although
the role of hr-HPV in lung cancers requires further
study. To the best of our knowledge, this is the first
study reporting the role of HPV genes expression in
EMT and the association between this virus and chronic
inflammation in lung cancer patients.
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